XBiotech is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. Co. has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. An area of medical focus for Co. are therapies that block a substance naturally produced by body, known as interleukin-1 alpha, that mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting and inflammation. Co.'s product development includes: Natrunix program, which is for the indication of pancreatic cancer and rheumatoid arthritis, and Hutrukin program, which is for the indication of stroke. The XBIT average annual return since 2015 is shown above.
The Average Annual Return on the XBIT average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XBIT average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XBIT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free XBIT Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
